Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Neurology

How Does PABPN1 GCN Repeat Length Affect OPMD Severity?

At a Glance

In OPMD, the PABPN1 gene has a genetic "stutter" called a GCN repeat. While a healthy gene has 10 repeats, having 12 to 17 repeats causes the disease. Generally, higher repeat numbers (15-17) lead to an earlier onset and faster progression of muscle weakness, while shorter lengths result in a milder course.

When you look at your genetic test results for Oculopharyngeal Muscular Dystrophy (OPMD), the “GCN repeat” number represents a genetic “stutter” in the PABPN1 gene [1]. Everyone has this stutter, but the number of times it repeats determines whether or not a person will develop OPMD [1]. A higher repeat number generally indicates that symptoms may begin earlier in life and progress more rapidly, though your specific disease course depends on multiple factors [2][3].

Understanding the “GCN Repeat” Stutter

Genes are made of DNA letters. In the PABPN1 gene, there is a sequence of three letters—G, C, and N (where the third letter can vary, so your report might specifically say GCG or GCA repeats)—that repeats over and over [1]. This sequence tells your body to add an amino acid called alanine to the PABPN1 protein, creating what doctors call a polyalanine tract [4][5].

  • Normal length: A healthy PABPN1 gene typically has 10 repeats [1].
  • Pathogenic (disease-causing) length: In most people with OPMD, the gene stutters too many times, typically resulting in 12 to 17 repeats [1][2]. This is often called a polyalanine expansion on medical reports [2].

Because of this extra length, the body produces a protein with too much alanine [4]. These elongated proteins don’t fold properly and clump together inside muscle cells, forming intranuclear inclusions (protein aggregates) [6][7]. Over time, these clumps interfere with normal muscle function and cause the muscle cells to weaken [6][8]. While we cannot currently stop these clumps from forming, targeted therapies—like seeing a speech-language pathologist for swallowing strategies—can help manage the resulting muscle weakness.

How Repeat Length Affects Severity

For most people with typical OPMD expansions, symptoms usually begin in their 40s to 60s. However, research shows a clear link between the exact number of repeats—called the expansion length—and how OPMD affects the body [2].

  • Age of onset: Individuals with longer expansions (such as 15, 16, or 17 repeats) tend to experience their first symptoms, like drooping eyelids (ptosis) or swallowing difficulties (dysphagia), at a younger age [3][5].
  • Disease progression: Longer repeat lengths are also associated with more severe disease and faster progression of muscle weakness [2][3]. The larger the expansion, the more frequently the proteins tend to clump together [5].
  • Shorter expansions: Those with shorter expansions (like 12 or 13 repeats) often notice their first symptoms later in adulthood and may experience a slower, milder disease course [2].

Inheriting One Mutated Copy vs. Two

Because humans inherit two copies of every gene—one from each parent—your genetic test will usually show two numbers for the PABPN1 gene.

  • Heterozygous (One mutated copy): Most people with OPMD are heterozygous, meaning they have one normal copy (usually 10 repeats) and one expanded copy (12-17 repeats) [9]. Because OPMD is mostly autosomal dominant, having just one expanded copy is enough to cause the disease [1][4]. If you have this dominant form, a genetic counselor can help explain the 50% chance of passing it to each of your children.
  • Homozygous (Two mutated copies): In rare cases, a person inherits an expanded copy from both parents [10]. Inheriting two mutated copies can lead to earlier or more severe symptoms, including significant neck muscle weakness (a very rare complication sometimes called dropped-head syndrome) [10][2].
  • The 11-Repeat Variant: Having 11 repeats is usually considered a normal or low-risk variant [1][2]. However, if a person inherits two 11-repeat copies (11/11), it can act as a recessive mutation and cause an atypical or milder form of OPMD [10][11].

The Numbers Aren’t the Whole Story

While the GCN repeat number is a helpful clue, it is not a perfect crystal ball. Significant variability exists even among people with the exact same repeat length [12]. Two family members with the same genetic test results might experience symptom onset at entirely different ages [12][2]. Other undiscovered genetic modifiers and cellular mechanisms likely influence how well your muscle cells handle the protein clumps [3][13].

You should use your repeat numbers to plan proactively with your medical team. For example, knowing your numbers can prompt you to establish baseline tests with a neurologist or see a speech-language pathologist early to monitor your swallowing function. Do not assume your disease timeline is strictly dictated by the numbers on your test report.

Common questions in this guide

What is a normal PABPN1 GCN repeat number?
A healthy PABPN1 gene typically has 10 repeats. When the gene stutters and creates 12 to 17 repeats, it causes oculopharyngeal muscular dystrophy (OPMD).
Does a higher repeat number mean worse OPMD symptoms?
Generally, yes. Individuals with longer expansions, such as 15 to 17 repeats, tend to experience earlier symptom onset and a faster progression of muscle weakness compared to those with shorter expansions.
What does it mean if my OPMD results say heterozygous?
Heterozygous means you inherited one normal copy of the PABPN1 gene and one mutated copy with an expanded repeat. Because OPMD is typically dominant, having just one expanded copy is enough to cause the condition.
What happens if both copies of the PABPN1 gene are mutated?
Inheriting a mutated copy from both parents, known as being homozygous, is very rare. It typically leads to symptoms starting at an earlier age and more severe muscle weakness, including difficulty holding the head up.
Will my symptoms definitely start at a specific age based on my repeat number?
No, the GCN repeat number is not a perfect predictor. Family members with the exact same genetic test results can experience their first symptoms at completely different ages due to other genetic and biological factors.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are the specific repeat numbers for both of my PABPN1 alleles, and are they listed as GCG or GCA on the lab report?
  2. 2.Based on my specific repeat expansion length, what is the typical age range when symptoms might begin or accelerate?
  3. 3.Are my genetic results considered heterozygous or homozygous, and how does that influence how closely you will monitor my symptoms?
  4. 4.Should I be referred to a speech-language pathologist now for a baseline swallowing evaluation, even if I currently feel fine?
  5. 5.Can you refer me to a genetic counselor to discuss what my specific mutation means for my children and extended family?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    [Haplotype Analysis of Oculopharyngeal Muscular Dystrophy (OPMD) Locus in Yakutia].

    Marusin AV, Kurtanov KhA, Maksimova NR, et al.

    Genetika 2016; (52(3)):376-84.

    PMID: 27281858
  2. 2

    Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy.

    Richard P, Trollet C, Stojkovic T, et al.

    Neurology 2017; (88(4)):359-365 doi:10.1212/WNL.0000000000003554.

    PMID: 28011929
  3. 3

    Clinical and genetic features of a large homogeneous cohort of oculopharyngeal muscular dystrophy patients from the Canary Islands.

    Alonso-Pérez J, de León Hernández JC, Pérez-Pérez H, et al.

    European journal of neurology 2022; (29(5)):1488-1495 doi:10.1111/ene.15252.

    PMID: 35112761
  4. 4

    Oculopharyngeal muscular dystrophy (OPMD) associated alanine expansion impairs the function of the nuclear polyadenosine RNA binding protein PABPN1 as revealed by proximity labeling and comparative proteomics.

    Mezzell AT, Zhang Y, Perez AM, Vest KE

    PLoS genetics 2026; (22(1)):e1011743 doi:10.1371/journal.pgen.1011743.

    PMID: 41587185
  5. 5

    Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy.

    Roth F, Dhiab J, Boulinguiez A, et al.

    Acta neuropathologica 2022; (144(6)):1157-1170 doi:10.1007/s00401-022-02503-7.

    PMID: 36197469
  6. 6

    Nuclear Protein Aggregates Disrupt RNA Processing and Alter Biomechanics in a Muscle Cell Model of OPMD.

    Shademan M, Flannery S, Bos E, et al.

    Aging and disease 2025; doi:10.14336/AD.2025.0699.

    PMID: 40901980
  7. 7

    Oculopharyngeal muscular dystrophy misdiagnosed as myasthenia gravis: Case report and review of literature.

    Aryani O, Akbari M, Aghsaei-Fard M, et al.

    Iranian journal of neurology 2017; (16(2)):98-99.

    PMID: 28761633
  8. 8

    Mitochondrial localization of PABPN1 in oculopharyngeal muscular dystrophy.

    Doki T, Yamashita S, Wei FY, et al.

    Laboratory investigation; a journal of technical methods and pathology 2019; (99(11)):1728-1740 doi:10.1038/s41374-019-0243-8.

    PMID: 30894671
  9. 9

    Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology.

    Vest KE, Phillips BL, Banerjee A, et al.

    Human molecular genetics 2017; (26(17)):3235-3252 doi:10.1093/hmg/ddx206.

    PMID: 28575395
  10. 10

    Dropped-head in recessive oculopharyngeal muscular dystrophy.

    Garibaldi M, Pennisi EM, Bruttini M, et al.

    Neuromuscular disorders : NMD 2015; (25(11)):869-72.

    PMID: 26494409
  11. 11

    PABPN1 (GCN)11 as a Dominant Allele in Oculopharyngeal Muscular Dystrophy -Consequences in Clinical Diagnosis and Genetic Counselling.

    Richard P, Trollet C, Gidaro T, et al.

    Journal of neuromuscular diseases 2015; (2(2)):175-180 doi:10.3233/JND-140060.

    PMID: 27858728
  12. 12

    Recurrent Pneumonia in a Patient With Oculopharyngeal Muscular Dystrophy (OPMD) due to GCN Expansion in the PABPN1 Gene: A Diagnostic Challenge.

    Mañana Valdés C, Arias Guillén M, Moris de la Tassa G

    Open respiratory archives 2026; (8(2)):100580 doi:10.1016/j.opresp.2026.100580.

    PMID: 41676387
  13. 13

    A Case of Oculopharyngeal Muscular Dystrophy Caused by a Novel PABPN1 c.34G > T (p.Gly12Trp) Point Mutation without Polyalanine Expansion.

    Takahashi Y, Morimoto N, Nada T, et al.

    Journal of neuromuscular diseases 2023; (10(3)):459-463 doi:10.3233/JND-221669.

    PMID: 36847015

This page explains PABPN1 genetic test results for educational purposes only. Always consult your neurologist or genetic counselor to accurately interpret your specific OPMD report.

Get notified when new evidence is published on Oculopharyngeal muscular dystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.